Objective. The aim of this study was to assess the therapeutic effects of biological DMARDs (bDMARDs) on the diversity of immune cell phenotypes in peripheral blood of patients with RA.
Introduction
RA is a systemic inflammatory disease that manifests clinically with polyarthritis and joint destruction [1] . The pathological processes of RA include immune cell differentiation into functionally distinct subsets that cause persistent inflammation and autoimmunity associated with interactive activation of T cells, B cells, monocytes and dendritic cells [2] . While the phenotype of immune cells is known to be different between peripheral blood and the inflamed synovium, it is difficult to obtain samples from affected joints in routine clinical practice. Nevertheless, immunophenotyping of peripheral blood cells provides useful information about the RA pathological process since these cells orchestrate the immune response.
Flow cytometry is the most powerful technology for proving cellular phenotype and function in the immune system by measuring multiple parameters on various individual cells. In fact, a comprehensive eight-colour flow cytometric analysis for the human immune system termed the Human Immunology Project (HIP) by the National Institutes of Health and the Federation of Clinical Immunology Societies was introduced as the standardized assay for immunophenotyping in human diseases [3] . This project is an effort to generate standardization of the flow cytometry assay. The assay relies on the development of robust standardized protocols for sample handling to enable reproducible results within and between institutions. Assessment of the phenotype of immune cells in RA and other autoimmune diseases can provide the following information: differentiation stage of lymphocytes such as naïve T cells and effector memory T cells; differences in lineage or functional differences represented by Th1 and Th2 cells; and activation status or involvement of cellular signalling molecules in the pathological process. Biological DMARDs (bDMARDs), such as TNF inhibitors, have revolutionized the treatment of RA, producing significant improvement in clinical and structural outcomes. In addition to TNF inhibitors, tocilizumab, which targets IL-6, and abatacept, which targets co-stimulation signals between T cells and antigen-presenting cells, have been introduced with excellent therapeutic effects [12, 13] . Based on the ACR/EULAR recommendation 2013, abatacept and tocilizumab are regarded as the first line biologics, together with TNF inhibitors, in the treatment of RA, especially in patients refractory to MTX [14] . However, it is difficult at present to predict the response to various bDMARDs especially since they have different modes of action. Moreover, little is known about the pathological immune cell subsets that are targeted by bDMARDs. In this regard, immunophenotyping of peripheral blood may help us understand the pathogenesis of RA and select the most appropriate biologics for the individual patient [15, 16] .
Based on this background, we designed the present study to analyse peripheral blood samples of RA patients using the HIP protocol customized to include staining of Tfh cells. The objectives of the study were to determine the relationship between peripheral immune cell phenotype and clinical manifestations; to determine the effects of different bDMARDs on various immune cell phenotypes; and to identify markers for response to treatment with bDMARDs in RA patients.
Methods

Patients
Patients were diagnosed according to ACR/EULAR 2010 criteria for RA. The patients who had received DMARD therapy at our hospital between 2012 and 2015 were targeted for inclusion in the present study. Of these, 108 patients were selected based on the following criteria: DAS28 ESR score of >3.1 for RA activity despite treatment with adequate doses of synthetic DMARDs including MTX for a minimum of 3 months, and no or moderate clinical response, according to the EULAR improvement criteria. At study entry, the patients continued their treatment including MTX and were concomitantly treated with bDMARDs such as various TNF inhibitors (n = 46; infliximab 6, etanercept 8, adalimumab 30, golimumab 1 and certolizumab pegol 1), abatacept (n = 40) or tocilizumab (n = 22). All patients who started treatment with bDMARDs at our hospital were registered in a retrospective observation study using anonymized data (the FIRST registry). bDMARD therapy was administered applying standard or recommended dosing and routes of administration.
We also included 33 age-and sex-matched healthy controls (HCs), who were either staff members of our hospital or subjects who visited our hospital for medical examination. Exclusion criteria for HC were inflammation, malignancy, autoimmune disorders or use of immunosuppressive therapy. The Human Ethics Review Committee of our university reviewed and approved this study, including the collection of peripheral blood samples from the control and RA groups. Each subject provided a signed consent form.
Measurements
The background factors investigated were age, sex, duration of RA and MTX, and corticosteroids. We also evaluated the severity of morning stiffness, number of swollen joints, number of tender joints and patient-evaluated pain and overall evaluation by a visual analogue scale, in addition to evaluation by the attending physician. The laboratory tests included CRP, ESR, MMP-3, RF and ACPA. Serum MMP-3 levels were examined using the latex agglutination turbidimetric immunoassay method (Kyurin Medical Laboratory, Kitakyushu, Japan). The variables investigated included DAS28-ESR, simplified disease activity index (SDAI), HAQ disability index and history of biologics use.
Flow cytometric analysis
All patients who were introduced to treatment with bDMARDs for the first time were registered for immunophenotyping analysis using multi-colour flow cytometry (the FLOW registry). After obtaining informed consent, blood was withdrawn during routine laboratory screening. All collected samples were immediately analysed by flow www.rheumatology.oxfordjournals.org cytometry. Peripheral blood mononuclear cells from 33 HCs and 108 bio-naïve RA patients were isolated from peripheral blood samples using lymphocyte separation medium (ICN/Cappel Pharmaceuticals, Aurora, OH, USA). In RA patients treated with bDMARDs, the blood samples were taken at baseline and at week 24 during treatment.
Peripheral blood mononuclear cells were resuspended in PBS/3% human IgG (Baxter International Inc., Vienna, Austria) in order to block Fc receptors and prevent nonspecific antibody binding, and then incubated for 15 min at 4 C in the dark. Afterwards, the cells were washed with PBS containing 1% BSA. Background fluorescence was assessed using appropriate isotype-and fluorochromematched control mAbs. After staining with the indicated antibodies (supplementary Table S1, available Differences between groups were compared using Student's t-test or Tukey's test. Correlation analysis was performed using Pearson's correlation coefficient. The paired t-test was used to detect statistically significant differences between baseline data and those measured at week 24. All reported P-values were two-sided and were not adjusted for multiple testing. The level of significance was set at P < 0.05. All analyses were conducted using JMP version 11.0 (SAS Institute Inc., Cary, NC, USA) or SPSS Statistics version 22.0 (IBM Corp., Armonk, NY, USA).
Results
Baseline characteristics
The baseline characteristics of RA patients are described in Table 1 . The mean age was 62.2 years and the majority of participating patients were woman (86.1%). On the other hand, the HCs comprised 9 males and 24 females with an average age of 58.7 (12.4) years. The mean duration of RA disease was 6.6 years. The mean disease activity at baseline was 27.6 and 5.5 for SDAI and DAS28-ESR, respectively. The mean HAQ disability index (HAQ-DI) scores were 1.2. At baseline, 82.4% of the patients were being treated with MTX while 20.4% were on oral steroids. Other laboratory findings included mean RF, ACPA, MMP-3, ESR and CRP levels of 118.4 U/ ml, 330.8 U/ml, 257.1 ng/ml, 49.4 mm/h and 2.2 mg/dl, respectively. The baseline characteristics and disease activity were different among the patients treated with different bDMARDs (supplementary Table S2 , available at Rheumatology Online). The TNF inhibitor group included significantly younger subjects while patients of the tocilizumab group had significantly higher disease activity scores such as SDAI and DAS28-ESR.
High proportion of Tfh cells, double negative B cells and pDCs in RA patients
First, we examined the properties of immune cell phenotypes in peripheral blood of RA patients in the context of differentiation stage of lymphocytes. However, no difference in T cell differentiation stage was observed ( Fig. 1 ; supplementary Fig. S2 and Table S3 , available at Rheumatology Online).
We next assessed the properties of functional subsets of peripheral T cells in RA. Among Th cell subsets, Tfh cells, activated Tfh cells and naïve Treg cells were significantly higher (P < 0.001, P < 0.001, P = 0.01, respectively), but that of Th1 cells was significantly lower in RA (P = 0.02) Table S3 , available at Rheumatology Online). For B cell subsets, the proportion of IgM memory B cells was significantly lower (P < 0.001), while naïve and double negative B cells were higher in the RA group than the HC group (P = 0.01 and P = 0.04, respectively). The proportions of monocyte subsets were not significantly different, whereas those of mDCs were lower   FIG. 1 The proportion of peripheral immune cells in healthy control subjects and RA patients at baseline Differences in proportions of subsets of T cells (A), B cells (B) and dendritic cells (C) at baseline between patients with RA (n = 108) and healthy control (HC, n = 33) subjects were evaluated. Data are mean (S.D.) of the percentage of positive cells in each subset. The statistical difference was determined by Student's t-test. Difference with P < 0.05 was considered significant.
www.rheumatology.oxfordjournals.org and pDCs were higher in the RA than the HC group (P = 0.01 and P < 0.001, respectively) ( Fig. 1, supplemen Correlation among memory T cells, plasmablasts, autoantibody titres and disease activity score Next, we analysed the correlation between immune cell phenotypes and clinical features using the Pearson product-moment correlation coefficient. The results showed a close correlation among proportions of effector memory Th cells, central memory cytotoxic T cells and serum ACPA titres (P = 0.03 and P = 0.01, respectively) ( Table 2 ). On the other hand, the proportion of naïve cytotoxic T cells correlated negatively with ACPA (P = 0.03). The proportions of central memory cytotoxic T cells, Th17 cells and Tfh cells correlated positively (P = 0.02, P = 0.01 and P = 0.01, respectively), whereas that of naïve Th cells correlated negatively with RF titres (P = 0.01) ( Table 2 ). It is noteworthy that the proportion of plasmablasts correlated positively with DAS28-ESR, SDAI, CRP and ESR (P = 0.01, P = 0.03, P = 0.01 and P = 0.03, respectively), whereas that of IgM memory B cells correlated negatively with ESR (P = 0.04) ( Table 2 ). The proportion of mDCs correlated negatively with disease activity markers ( Table 2 ). The percentage of classical monocytes correlated positively with SDAI (P = 0.04), whereas the proportion of non-classical monocytes correlated negatively with SDAI (P = 0.04) ( Table 2) .
The above results suggest that abnormal T cell differentiation might be associated with autoantibody production and that the high proportion of plasmablasts could be associated with disease activity in RA.
Statistical clustering analysis among different lineage in T cells and B cells
To assess the correlation between various peripheral blood immune cell phenotypes, we determined the Pearson product-moment correlation coefficient and the correlation clustering. The differentiation status classified as naïve or memory phase and activation status was clustered with same status in different cell types, for example, T cells or B cells, indicating the reliability of this approach (supplementary Fig. S4 , available at Rheumatology Online). It is noteworthy that the proportion of Fig. S4A S4B, available at Rheumatology Online). However, the proportion of plasmablasts did not cluster with that of IgM memory B cells (supplementary Fig. S4A and S4B, available at Rheumatology Online). The proportion of Tfh cells clustered significantly with that of Th17 cells (supplementary Fig. S4B , available at Rheumatology Online).
Differential changes in peripheral immune cell phenotypes by bDMARDs
Treatment with TNF inhibitors, abatacept and tocilizumab resulted in marked improvement in the disease activity scores, such as DAS28-ESR, at 24 weeks post-treatment and the extent of the reduction was comparable among the treatment groups (supplementary Fig. S5 , available at Rheumatology Online).
Next, we assessed changes in immune cell phenotypes at 24 weeks after biologics treatment. Treatment with bDMARDs resulted in significant decreases in the proportions of naïve cytotoxic T cells, Treg, activated Tfh cells and pDCs (P < 0.01, P < 0.01, P = 0.03 and P < 0.01, respectively), and in significant increases in effector memory cytotoxic T cells, Th1 and IgM memory B cells (P < 0.01, P = 0.01 and P = 0.03, respectively) ( Table 3; supplementary  Table S4 , available at Rheumatology Online). Interestingly, the immune phenotype showed various changes after treatment with different types of bDMARDs. For example, treatment with TNF inhibitors decreased the proportion of naïve T cells (P = 0.01 for Th cells, P < 0.01 for cytotoxic T cells) but increased that of effector memory T cells, Th17 cells, Tfh cells and IgM memory B cells (P < 0.01, P = 0.01, P = 0.03 and P = 0.02, respectively). Furthermore, treatment with TNF inhibitors significantly decreased the proportion of pDCs (P = 0.02). Changes in proportions of immune cell phenotypes (change = proportion after 24-week treatment with bDMARDs proportion at baseline) were calculated. The level of significance was considered P < 0.05 and values below this are marked with an asterisk and shown in bold.
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Treatment with abatacept produced the most significant changes in lymphocyte phenotypes. Abatacept significantly decreased the proportion of naïve cytotoxic T cells (P = 0.02) but increased that of naïve Th cells and effector memory cytotoxic T cells (P = 0.04 and P < 0.01, respectively). The most interesting result was that abatacept markedly reduced the frequency and number of peripheral Tfh and activated Tfh cells (P < 0.01 and P < 0.01, respectively) ( Table 3 and Fig. 2; supplementary Table S4 , available at Rheumatology Online). Contrary to TNF inhibitors, abatacept significantly reduced the percentage of Th17 cells and Treg cells (P < 0.01 and P < 0.01, respectively).
Treatment with tocilizumab significantly reduced the frequency of double negative B cells (P = 0.02) but increased that of myeloid DCs (P = 0.03). Although not significant, tocilizumab tended to increase the proportion of Treg cells and decrease that of plasmablasts.
Prediction of response to bDMARDs by peripheral immunophenotyping analysis
Finally, we performed sub-analyses to identify factors associated with the response to treatment. Immunophenotyping of the baseline prognostic factors that could predict percentage improvement in DAS28-ESR at week 24 identified the proportion of Tfh cells at baseline as an independent and significant factor in the abatacept group, with a standardized partial regression coefficient of À0.34 (P = 0.04) ( Table 4 ). In contrast, the proportion of naïve cytotoxic T cells was a significant independent factor associated with poor response to abatacept therapy, with a standardized partial regression coefficient of 0.36 (P = 0.03). With regard to the response to TNF inhibitors therapy, the proportion of pDCs was identified as a significant and independent factor (Table 4) , with a standardized partial regression coefficient of À0.34 (P = 0.03). On the other hand, we could not find any marker for the response to tocilizumab therapy (Table 4) .
Discussion
In this study, we showed that high proportions of Tfh cells, double negative B cells and pDCs were characteristic of patients with active RA. The proportion of memory and effector phase T cells correlated with titres of autoantibodies, such as ACPA and RF, while a high proportion of plasmablasts correlated with disease activity. The results also showed that different bDMARDs resulted in different changes in immune cell subsets, for example, abatacept characteristically reduced Th subsets, mainly Tfh and Th17 cells, whereas TNF inhibitors reduced pDCs but increased Tfh and Th17 cells, and tocilizumab reduced double negative B cells but increased Treg cells. Finally, we identified the phenotypes that could predict the response to bDMARDs, for example, the proportion of Tfh cells at baseline was an independent predictor of the response to abatacept.
Immunophenotypic analysis showed a close relationship between abnormal T cell differentiation and autoantibody production. Among Th subsets, the proportion of Tfh cells was characteristically elevated in RA patients and closely correlated with RF titre. Similarly, the proportion of Th17 cells correlated with RF. In cluster analysis, Th17 and Tfh formed a statistical cluster, indicating similarity of each subset with regard to function and differentiation. These results are similar to previous studies, which also found high proportions of Tfh and Th17 cells in peripheral blood and synovial fluid [1720] . The results suggest important roles of Tfh and Th17 cells in autoimmunity of RA, at least in part through autoantibody production. In contrast, the proportion of circulating plasmablasts was associated with disease activity. The proportion of plasmablasts clustered with that of the central memory phase of T cells and memory B cells. Plasmablasts not only secrete antibodies but also can possess an antigen-presenting capacity to T cells and promote T cell differentiation [21] . Thus, plasmablasts may play an important role in maintaining persistent joint inflammation through their interactive association with memory T cells.
Our results identified the immune cell phenotypes that correlated negatively with disease activity. Low proportions of IgM memory B cells and mDCs were found in RA patients and correlated negatively with markers of inflammation, such as ESR and CRP, as well as with
FIG. 2 Effects of treatment with bDMARDs on the number of T follicular helper cells in peripheral blood
The number of peripheral Tfh cells (cells/ml) before and after 24-week treatment with TNF inhibitors, abatacept and tocilizumab was measured. *P < 0.05, **P < 0.01. disease activity scores, such as DAS28-ESR and SDAI. The proportion of IgM memory B cells did not cluster with other memory or effector B cell populations, suggesting that this subset is functionally independent from other B cells. Khoder et al. [22] found recently a high proportion of B regulatory cells, which suppresses the immune response, within the IgM memory B cell population. Thus, the low proportion of this subset may reflect impaired immunomodulation in RA. Furthermore, Richez et al. [23] demonstrated that low proportion of circulating mDCs correlated inversely with disease activity, and this finding was confirmed in the present study. Jongbloed et al. [24] also reported that the number of circulating mDCs was inversely correlated with CRP and that mDCs in RA peripheral blood showed immature phenotype with potent ability of cytokine production. Furthermore, it is reported that the percentage of mDCs was increased in the inflamed synovial tissue [25] , suggesting that a low proportion of circulating mDCs may in part reflect the migration of mDCs into inflamed synovia.
Administration of bDMARDs resulted in heterogeneous changes in immune cell subsets, as demonstrated by immunophenotyping analysis, although all types of bDMARDs used in the present study improved the disease activity. This may indicate the diversity of immunopathogenic process in RA. As expected, abatacept inhibited the activation and differentiation of Th cell subsets. Even among these cells, Tfh cells might be a potential target for abatacept therapy. Platt et al. [26] reported that abatacept decreased Tfh cells in mice. We reported previously that treatment with [17, 18, 28, 29] . In the present study, we showed that the proportion of Tfh cells was an independent marker of the therapeutic efficacy of abatacept. Based on these findings, we conclude that abatacept selectively controls Tfh differentiation, leading to a reduction in autoantibody production. On the other hand, TNF inhibitors did not reduce the proportion of effector T cells but rather increased those of Tfh and Th17 cells. This suggests abnormal regulation of T cell differentiation independent of TNF-mediated inflammation in this disease. In support of this concept, TNF inhibitors are more effective in patients seronegative for RF and ACPA [30] . In addition, TNF inhibitors increased the proportion of IgM memory B cells. As noted, B regulatory cells might be included in this population and the recovery of IgM memory B cells by TNF blockade may reflect improvement of the inflammatory and immunomodulatory condition. Surprisingly, TNF inhibitors significantly reduced the proportion of pDCs and the baseline levels of pDCs were identified as a predictor of the response to treatment with TNF inhibitors. The reason for the reduction in circulating pDCs after TNF blockade is not clear at present. It has been reported that TNF blockade enhanced the production of type I IFNs and transcription of type I IFN-inducible genes [31, 32] . We previously reported that type I IFNs promote Tfh cell differentiation [33] . Indeed, the proportion of Tfh cells was increased after the treatment with TNF inhibitors. Although pDCs are specialized to produce type I IFNs, type I IFN itself is known to negatively control pDC survival via the intrinsic apoptosis pathway [34] . Thus, we speculate that one of the possible reasons for the decrease in circulating pDCs and for the increase in Tfh cells could be that they are the result of increased levels of type I IFNs by TNF-a inhibition. Further studies are needed to determine whether this is likely to be due to immunomodulatory mechanisms other than neutralization of TNF-a.
In contrast to other biologics, tocilizumab affected the property of B cell subsets. Notably, tocilizumab significantly decreased the proportion of double negative B cells. Although the characteristics of double negative B cells are not well established, this population is recognized as part of the memory compartment [35, 36] . Mahmood et al. [35] demonstrated inverse correlation between the percentage of double negative B cells at baseline and the response to tociluzimab therapy. These findings may not be surprising because IL-6 is an important cytokine for B cell differentiation. Although not significant, tocilizumab tended to increase the proportion of Treg cells and decrease that of plasmablasts, consistent with previous results reported by other investigators [3739] . As noted above, the recovery of the proportion of mDCs by tocilizumab suggests their release from inflamed synovium as a result of improvement of disease activity. However, since the number of patients treated with tocilizumab was small compared with those treated with other bDMARDs, we cannot rule out type 2 error in the reported results of the tocilizumab group.
The present study has certain limitations. First, the properties of each drug cannot simply be compared because this was an observational study and participants were subject to selection bias. Nevertheless, we believe that the results are applicable to clinical practice because the study represents a real world setting. Second, the immune phenotype was evaluated by the proportions of peripheral blood cells only and not that in the inflamed synovia. In future, in-depth study coupled with evaluation of the exact number of the cells in peripheral blood and in synovial tissues may be more useful.
In conclusion, the present study highlighted the diversity of immunopathogenesis in patients with RA. Our results demonstrated that the percentage of Tfh cells was a marker of the response to treatment with abatacept and the latter markedly reduced the proportion of activated Tfh cells. Immunophenotypic analysis might be useful in evaluating the immune signatures and in predicting the therapeutic efficacy for individual patients. 
